Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Maze Therapeutics, a kidney disease therapy developer, recently IPO-ed with a market cap of $487mn and significant early-stage investor backing. Lead asset MZE829 targets APOL1 Kidney Disease ...

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

In a recent SEC filing, Metsera said it was looking to offer 17.2M shares priced between $15 and $17, which would raise around $275M if priced at the midpoint.Underwriters would be granted a 30 ...

Furthermore, Metsera’s IPO opened 42% higher on the Nasdaq Global Select Market, with several financial firms acting as joint bookrunners for the offering. These developments indicate a strong ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...

“2024 was a year of exceptional execution and acceleration at Metsera (MTSR),” said Whit ... With the completion of our recent IPO, we have substantial capital to continue this momentum ...

Aardvark’s IPO comes amid an uptick in biotech ... far in 2025 include obesity drug developer Metsera, Sionna Therapeutics, kidney disease startup Maze Therapeutics, and Ascentage Pharma.

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the ...

Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli Lilly (NYSE:LLY) on Thursday after the Indiana-based pharma giant reported ...

Furthermore, Metsera’s IPO opened 42% higher on the Nasdaq Global Select Market, with several financial firms acting as joint bookrunners for the offering. These developments indicate a strong ...

With the completion of our recent IPO, we have substantial capital to continue this momentum, enabled by our highly experienced team and committed partners. We expect 2025 to be another year of ...